Selecta Biosciences Announces Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update
New Data from Ongoing SEL-212 Phase 2 Trial Show Persistent Clinical Activity After Repeat Administration in Symptomatic Gout Patients Emerging Clinical and Preclinical Data Confirm the Broad Potential of Selecta’s Immune Tolerance Platform to Enable …